ClearB Therapeutics Announces First Patient Dosed in a Phase 1b
First in Human Study of CLB-3000 and a Presentation at AASLD 2023 of Preclinical data both for the Treatment of Chronic Hepatitis B InfectionCONCORD, Mass.--(BUSINESS WIRE)--ClearB Therapeutics, Inc., now a clinical-stage biotechnology company committed to developing therapies to drive functional cure in patients wi...